Skip to main content
MIRA
NASDAQ Life Sciences

MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Ketamir-2 Results; DEA Confirms Not Controlled Substance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$0.975
Mkt Cap
$40.803M
52W Low
$0.9
52W High
$2.45
52W Position info
8.3% above low
Off High info
60% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

MIRA is trading near its 52-week low of $0.9 (8.3% above the low).

Summary

MIRA Pharmaceuticals announced positive unblinded Phase 1 results for Ketamir-2, showing strong safety and a favorable pharmacokinetic profile, alongside a crucial DEA ruling that the drug is not a controlled substance.


Key Events · Product Development and Regulatory · MIRA

  • Positive Unblinded Phase 1 Results

    Ketamir-2 showed strong safety and tolerability in 57 healthy volunteers, with fewer adverse events reported in the treatment group compared to placebo.

  • Favorable Pharmacokinetics

    The drug demonstrated rapid oral absorption, dose-proportional exposure, and a half-life supporting potential once-daily administration.

  • DEA Not a Controlled Substance

    The U.S. Drug Enforcement Administration determined that Ketamir-2 is not classified as a controlled substance, significantly de-risking its regulatory and commercial path.

  • Advancing to Phase 2a

    The company is preparing for Phase 2a clinical protocol submission to the FDA for evaluation in chemotherapy-induced peripheral neuropathy (CIPN).


Analysis · MIRA · Life Sciences

This filing provides critical positive unblinded Phase 1 clinical trial results for Ketamir-2, demonstrating a strong safety profile with fewer adverse events than placebo, and a pharmacokinetic profile supporting once-daily dosing. The most significant update is the U.S. DEA's determination that Ketamir-2 is not classified as a controlled substance, which substantially de-risks the drug's commercial pathway and broadens its market potential. This positive development is particularly important for a company that recently issued a going concern warning.

How filings like this one have moved

In the 30 days to Nov 5, 2026, 50.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.71%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MIRA was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.8M. The 52-week trading range was $0.90 to $2.45. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MIRA - Latest Insights

MIRA
Oct 28, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.5561
Real-time Price: $0.561 info
Change: +$0.0049 (+0.88%) info
Market Cap: $23.574M info
MIRA
Oct 22, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.681
Real-time Price: $0.561 info
Change: -$0.120 (-18%) info
Market Cap: $23.574M info
MIRA
Sep 17, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7101
Real-time Price: $0.561 info
Change: -$0.1491 (-21%) info
Market Cap: $23.574M info
MIRA
Sep 17, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7101
Real-time Price: $0.561 info
Change: -$0.1491 (-21%) info
Market Cap: $23.574M info
MIRA
Aug 12, 2026, 4:17 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.7387
Real-time Price: $0.561 info
Change: -$0.1777 (-24%) info
Market Cap: $23.574M info